Tworowska Izabela, Ranganathan David, Thamake Sanjay, Delpassand Ebrahim, Mojtahedi Alireza, Schultz Michael K, Zhernosekov Konstantin, Marx Sebastian
RadioMedix Inc., Houston, TX, USA.
RadioMedix Inc., Houston, TX, USA.
Nucl Med Biol. 2016 Jan;43(1):19-26. doi: 10.1016/j.nucmedbio.2015.08.004. Epub 2015 Sep 1.
68Ga-DOTATATE is a radiolabeled peptide-based agonist that targets somatostatin receptors overexpressed in neuroendocrine tumors. Here, we present our results on validation of organic matrix 68Ge/68Ga generators (ITG GmbH) applied for radiosynthesis of the clinical doses of 68Ga-DOTATATE (GalioMedixTM).
The clinical grade of DOTATATE (25 μg±5 μg) compounded in 1 M NaOAc at pH=5.5 was labeled manually with 514±218 MBq (13.89±5.9 mCi) of 68Ga eluate in 0.05 N HCl at 95°C for 10 min. The radiochemical purity of the final dose was validated using radio-TLC. The quality control of clinical doses included tests of their osmolarity, endotoxin level, radionuclide identity, filter integrity, pH, sterility and 68Ge breakthrough.
The final dose of 272±126 MBq (7.35±3.4 mCi) of 68Ga-DOTATATE was produced with a radiochemical yield (RCY) of 99%±1%. The total time required for completion of radiolabeling and quality control averaged approximately 35 min. This resulted in delivery of 50%±7% of 68Ga-DOTATATE at the time of calibration (not decay corrected).
68Ga eluted from the generator was directly applied for labeling of DOTA-peptide with no additional pre-concentration or pre-purification of isotope. The low acidity of 68Ga eluate allows for facile synthesis of clinical doses with radiochemical and radionuclide purity higher than 98% and average activity of 272±126 MBq (7.3±3 mCi). There is no need for post-labeling C18 Sep-Pak purification of final doses of radiotracer. Advances in knowledge and implications for patient care. The clinical interest in validation of 68Galabeled agents has increased in the past years due to availability of generators from different vendors (Eckert-Ziegler, ITG, iThemba), favorable approach of U.S. FDA agency to initiate clinical trials, and collaboration of U.S. centers with leading EU clinical sites. The list of 68Ga-labeled tracers evaluated in clinical studies should growth because of the sensitivity of PET technique, the simplicity of the shakebake approach for the dose preparation and reliability of 68Ge/68Ga generators. Our studies have confirmed the reproducible elution profile, and high reliability of ITG GmbH generators required for routine doses preparation according to FDA recommendations.
68Ga-多柔比星是一种基于放射性标记肽的激动剂,可靶向神经内分泌肿瘤中过度表达的生长抑素受体。在此,我们展示了我们对用于临床剂量68Ga-多柔比星(GalioMedixTM)放射性合成的有机基质68Ge/68Ga发生器(ITG GmbH)进行验证的结果。
将在pH = 5.5的1 M醋酸钠中配制的临床级多柔比星(25 μg±5 μg)与514±218 MBq(13.89±5.9 mCi)的68Ga洗脱液在0.05 N盐酸中于95°C手动标记10分钟。使用放射性薄层色谱法验证最终剂量的放射化学纯度。临床剂量的质量控制包括渗透压、内毒素水平、放射性核素同一性、过滤器完整性、pH值、无菌性和68Ge突破测试。
生产出最终剂量为272±126 MBq(7.35±3.4 mCi)的68Ga-多柔比星,放射化学产率(RCY)为99%±1%。完成放射性标记和质量控制所需的总时间平均约为35分钟。这导致在校准(未进行衰变校正)时交付了50%±7%的68Ga-多柔比星。
从发生器洗脱的68Ga直接用于标记DOTA肽,无需对同位素进行额外的预浓缩或预纯化。68Ga洗脱液的低酸度允许轻松合成放射化学和放射性核素纯度高于98%且平均活度为272±126 MBq(7.3±3 mCi)的临床剂量。无需对放射性示踪剂的最终剂量进行标记后C18 Sep-Pak纯化。知识进展及对患者护理的意义。由于不同供应商(Eckert-Ziegler、ITG、iThemba)提供了发生器,美国食品药品监督管理局(FDA)机构启动临床试验的有利方式,以及美国各中心与欧盟领先临床站点的合作,过去几年对68Ga标记剂验证的临床兴趣有所增加。由于PET技术的敏感性、剂量制备的摇混方法的简便性以及68Ge/68Ga发生器的可靠性,临床研究中评估的68Ga标记示踪剂列表应该会增加。我们的研究证实了ITG GmbH发生器具有可重复的洗脱曲线和高可靠性,这是根据FDA建议制备常规剂量所必需的。